Imdatifan

N/A

Report date: 2026/04/22 20:01:10
NME

Base Information

Drug NameImdatifan
Drug Alias NameHIF-2 alpha inhibitor (NiKang Therapeutics)Hypoxia inducible factor 2 alpha inhibitor (NiKang Therapeutics)NKT-2152HS-10516HS10516 +[6] 
ClassificationSmall molecules
Mechanisms of ActionEndothelial PAS domain-containing protein 1 inhibitors
TargetsEndothelial PAS domain-containing protein 1
Therapy Area/IndicationsSolid tumoursHypoxiaKidney Diseases +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNiKang Therapeutics Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHansoh Pharmaceutical Group Company LtdJiangsu Hansoh Pharmaceutical Group Co LtdShanghai Hansoh Biomedical Co Ltd
Inactive CompaniesNiKang Therapeutics Inc
Active IndicationsSolid tumoursvon Hippel-Lindau DiseaseCarcinoma, Renal Cell
Inactive IndicationsHypoxiaKidney DiseasesUrologic Diseases +[10] 

Other Information

ATC CodeN/A
Related LinksN/A